BridgeBio Pharma, Inc.
(NASDAQ : BBIO)

( )
BBIO PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. -0.51%135.110.0%$892.11m
AMGNAmgen, Inc. 0.38%254.001.5%$855.18m
GILDGilead Sciences, Inc. 0.25%64.631.0%$546.18m
VRTXVertex Pharmaceuticals, Inc. 0.57%271.191.9%$490.50m
REGNRegeneron Pharmaceuticals, Inc. 0.92%689.702.6%$438.52m
ILMNIllumina, Inc. -0.41%242.583.3%$312.19m
NVAXNovavax, Inc. -0.26%46.9575.7%$257.78m
BIIBBiogen, Inc. 0.86%205.971.8%$234.70m
BNTXBioNTech SE 0.51%158.950.0%$212.05m
SNSSSunesis Pharmaceuticals, Inc. 0.00%2.100.7%$146.80m
EXASEXACT Sciences Corp. 0.96%50.3417.7%$129.43m
TECHBio-Techne Corp. 0.00%365.324.5%$100.31m
TXG10X Genomics, Inc. 0.00%47.350.0%$95.11m
BMRNBioMarin Pharmaceutical, Inc. 0.00%78.864.2%$94.54m
CRSPCRISPR Therapeutics AG 1.88%56.270.6%$81.91m

Company Profile

BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Frank McCormick, Philip Reilly, and Neil Kumar in 2015 and is headquartered in Palo Alto, CA.